

Pergamon Tetrahedron Letters 43 (2002) 5237–5239

## **Regiospecific synthesis of a bridgehead-functionalized bicyclo[2.2.2]octenone**

Andrew S. Kende,<sup>a,\*</sup> Jiong Lan<sup>a</sup> and Dorit Arad<sup>b</sup>

a *Department of Chemistry*, *University of Rochester*, *Rochester*, *NY* 14627-0216, *USA* b *Drug Design Department*, *eXegenics Inc*., *Dallas*, *TX* 75235, *USA*

Received 22 May 2002; accepted 4 June 2002

**Abstract—**Three independent strategies are tested toward the synthesis of the protected 1-aminobicyclo[2.2.2]octene ketodiester **1**. One of these three is found to be completely regioselective. It proceeds by Diels–Alder addition of dimethyl acetylenedicarboxylate to the silyl enol ether of 3-benzyloxycarbonyl-2-cyclohexenone, followed by a chemoselective Curtius rearrangement. © 2002 Elsevier Science Ltd. All rights reserved.

Bicyclo<sup>[2.2.2]</sup>octanes bearing a free or protected  $NH<sub>2</sub>$ group at the bridgehead have served as scaffolds for antiviral agents,  $1,2$  as inhibitors of phenylethanolamine *N*-methyl transferase<sup>3</sup> and as ligands for the phencyclidine<sup>4</sup> and dopamine<sup>5</sup> receptors. In contrast, the literature on analogous bicyclo[2.2.2]octenes is sparse,<sup>6</sup> and highly functionalized ring derivatives appear to be unknown. We now report a comparison of three synthetic strategies directed toward the protected amino ketone diester **1** in this series.



Our initial approach to **1** attempted to parallel earlier work by Wolinsky and Login toward bridgehead carbinols in this system.<sup>7</sup> Starting from 1,3-cyclohexanedione, we prepared the vinylogous urea **2**. <sup>8</sup> The latter was converted to an *O*,*N*-bis-silyl derivative, formulated as **3**. This was subjected to Diels–Alder reaction with dimethyl acetylenedicarboxylate to yield an adduct, expected to yield on mild acid hydrolysis the bridgehead carbamate **4**.

To our surprise, hydrolysis of the initial Diels–Alder adduct gave a product ketone devoid of nitrogen, namely the bridgehead hydroxy ketone **5** previously prepared by Wolinsky.<sup>7</sup> It thus became clear that the diene initially assigned structure **3** was in fact the regioisomer **3**, and that the isolation of **5** as the final product had proceeded by the parallel Diels–Alder sequence picture below. Thus, enolization of **2** had followed the pathway noted by Bryson and Gammill, involving enolization at C(4) of the cyclohexenone system.<sup>9</sup>



*Keywords*: Diels–Alder reaction; enols and derivatives; Curtius rearrangement; bicyclooctenones; regiospecificity. \* Corresponding author. Fax: 585-506-0205; e-mail: [kende@chem.rochester.edu](mailto:kende@chem.rochester.edu)



**Scheme 1.** *Reagents and conditions*: (a) i. 40°C, 2 days, ii. CH<sub>3</sub>I, CH<sub>2</sub>Cl<sub>2</sub>, iii. DBU, CH<sub>2</sub>Cl<sub>2</sub>, 67%; (b) dimethyl acetylenedicarboxylate, *N*,*N*-dimethylaniline, 80°C, 69%; (c) i. catecholborane, 2 mol% Rh(PPh<sub>3</sub>)<sub>3</sub>Cl, THF, then H<sub>2</sub>O<sub>2</sub>, Buffer pH 7.0, ii. DMSO, (COCl)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>,  $-78 \sim -60^{\circ}$ C, 55%; (d) i. 30% CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, ii. (COCl)<sub>2</sub>, DMF, CH<sub>2</sub>Cl<sub>2</sub>, iii. NaN<sub>3</sub>, acetone/H<sub>2</sub>O (3:1), iv. *t*-butanol, reflux, 63%.



**Scheme 2.** *Reagents and conditions*: (a) see Ref. 14; (b) TBSOTf, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0°C; (c) dimethyl acetylenedicarboxylate, 80°C, 66% from 10; (d) 1 M TBAF, THF, 91%; (e) Raney-Ni, ethanol, (f) i. (COCl)<sub>2</sub>, DMF, CH<sub>2</sub>Cl<sub>2</sub>, ii. NaN<sub>3</sub>, acetone/H<sub>2</sub>O (3:1), iii. *t*-butanol, reflux, 55% from **13**.

To overcome this problem, we sought to introduce the bridgehead nitrogen by Curtius rearrangement.<sup>6</sup> Diels– Alder addition of 1-(*N*,*N*-dimethylamino)-1,3 butadiene<sup>10</sup> to  $t$ -butyl acrylate gave adducts which upon Hoffman elimination gave in 67% yield the diene ester 6.<sup>11</sup> Reaction of this ester with excess dimethyl acetylenedicarboxylate in the presence of 5 mol<sup>%</sup> Me<sub>2</sub>NPh gave  $69\%$  of the bicyclo<sup>[2.2.2]</sup>octadiene triester **7**, accompanied by ca. 10% of the *retro*-Diels– Alder product  $\hat{\mathbf{8}}$ .<sup>12</sup> Hydroboration of diene 7 with  $B_2H_6$ gave no selectivity. However, reaction with catecholborane and  $Rh(PPh<sub>3</sub>)<sub>3</sub>Cl$  as catalyst<sup>13</sup> proceeded with moderate regioselectivity to yield, after neutral  $H_2O_2$ workup and Swern oxidation, a 55% yield of the ketone **9**. Trifluoroacetic acid cleavage of the *t*-butyl ester, then successive conversion of the carboxyl group to acid chloride and then acyl azide, followed by overnight reflux in *t*-BuOH gave the desired target **1** in 63% yield from **9** (Scheme 1).16

Finally, a completely regioselective third approach to the protected aminoketone **1** was achieved starting from 2-cyclohexenone. Conversion of the latter to the 3-benzyloxycarbonyl derivative **10** by a known procedure<sup>14</sup> was followed by treatment of **10** with TBSOTf and  $Et_3N$  to give the diene ester  $11.^{15}$  Diels– Alder reaction of **11** with dimethyl acetylenedicarboxylate gave adduct **12** which on hydrolysis produced ketone **13** in 60% overall yield from **11**. Hydrogenation

of **13** over Raney-Ni chemoselectively produced the bicyclooctene acid **14**. Curtius rearrangement by the sequence described above gave the protected aminoketone **1** in 55% yield from **13**. The last route comprises an efficient sequence to this highly functionalized bicyclo[2.2.2]octene system (Scheme 2).16

## **References**

- 1. Whitney, J. G.; Gregory, W. A.; Kauer, J. C.; Roland, J. R.; Snyder, J. A.; Benson, R. E.; Hermann, E. C. *J*. *Med*. *Chem*. **1970**, 13, 254.
- 2. Smith, P. W.; Trivedi, N.; Howes, P. D.; Sollis, S. L.; Rahim, G.; Bethell, R. C.; Lynn, S. *Bioorg*. *Med*. *Chem*. *Lett*. **1999**, 9, 611.
- 3. Grunewald, G. L.; McLeish, M. J.; Criscione, K. R. *Bioorg*. *Med*. *Chem*. *Lett*. **2001**, 11, 1579.
- 4. Moriarty, R. M.; Enache, L. A.; Zhao, L.; Gilardi, R.; Mattson, M. V.; Prakash, O. *J*. *Med*. *Chem*. **1998**, 41, 468.
- 5. (a) Katz, J. L.; Izenwasser, S.; Terry, P. *Psychopharmacology* **2000**, 148, 90; (b) Wong, D. T.; Molloy, B. B.; Bymaster, F. P. *Neuropharmacology* **1977**, 16, 11.
- 6. Kauer, J. C. US Pat. 3,418,369 (1968) *Chem*. *Abst*. **1969**, 70, 106067.
- 7. Wolinsky, J.; Login, R. B. *J*. *Org*. *Chem*. **1970**, 35, 3205.
- 8. Ovenden, S. P. B.; Capon, R. J. *J*. *Org*. *Chem*. **1999**, 64, 1140.
- 9. Bryson, T. A.; Gammill, R. B. *Tetrahedron Lett*. **1974**, 15, 3963.
- 10. Botica, I.; Mirrington, R. N. *Aust*. *J*. *Chem*. **1971**, <sup>24</sup>, 1467 and references cited therein.
- 11. Delany, J. J.; Berchtold, G. A. *J*. *Org*. *Chem*. **1988**, 53, 3262.
- 12. Buckle, R. N.; Liu, P. Y.; Roberts, E. W. D.; Burnell, D. J. *Tetrahedron* **1999**, <sup>55</sup>, 11455.
- 13. (a) Burgess, K.; Ohlmeyer, M. J. *Chem*.*Rev*. **1991**, 91, 1179; (b) Brands, K. M. J.; Kende, A. S. *Tetrahedron Lett*. **1992**, 33, 5887.
- 14. (a) Lee, P. H.; Lee, B.; Lee, J.; Park, S. K. *Tetrahedron Lett*. **1999**, 40, 3427; (b) Lee, P. H.; Lee, B.; Lee, K.; Lee, C. H.; Chang, S. *Bull*. *Korean Chem*. *Soc*. **2000**, 21, 595.
- 15. Buckle, R. N.; Burnell, D. J. *Tetrahedron* **1999**, <sup>55</sup>, 14829.
- 16. Selected spectroscopic data; **7**: colorless oil; <sup>1</sup> H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  1.52 (s, 9H), 1.55–1.70 (m, 3H), 1.81–1.88 (m, 1H), 3.76 (s, 3H), 3.86 (s, 3H), 4.18–4.23 (m, 1H), 6.47 (dd, *J*=6.1, 7.4 Hz, 1H), 6.57 (dd, *J*=1.6,

7.4 Hz, 1H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  24.9, 27.8 (3×C), 30.2, 37.9, 51.97, 52.00, 55.3, 81.8, 133.1, 134.0, 137.8, 146.0, 164.1, 166.7, 170.7 ppm; anal. calcd for  $C_{17}H_{22}O_6$ : C, 63.34; H, 6.88. Found: C, 63.22; H, 6.84%; **9**: mp 144–145°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$ 1.52 (s, 9H), 1.80–1.90 (m, 1H), 1.95–2.05 (m, 3H), 2.38 (d, *J*=18.7 Hz, 1H), 2.48 (dd, *J*=2.5, 18.7 Hz, 1H), 3.79 (s, 3H), 3.79–3.82 (m, 1H), 3.84 (s, 3H) ppm; 13C NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  22.1, 27.6 (3×C), 29.0, 41.4, 48.7, 51.5, 52.2, 52.4, 82.5, 130.8, 146.6, 163.1, 166.0, 170.0, 206.6 ppm; anal. calcd for  $C_{17}H_{22}O_7$ : C, 60.35; H, 6.55. Found: C, 60.14; H, 6.46%; 1: mp 152-153°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  1.34 (s, 9H), 1.67-1.73 (m, 1H), 1.86–1.96 (m, 3H), 2.26 (d, *J*=18.4 Hz, 1H), 2.92 (dd, *J*=2.8, 18.4 Hz, 1H), 3.61–3.65 (m, 1H), 3.68 (s, 3H), 3.70 (s, 3H), 5.08 (brs. 1H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100) MHz): δ 21.6, 28.0 (3×C), 30.1, 43.5, 48.1, 52.2, 52.4, 57.5, 79.9, 130.0, 147.8, 154.4, 163.3, 165.4, 205.7 ppm; anal. calcd for  $C_{17}H_{23}NO_7$ : C, 57.78; H, 6.56; N, 3.96. Found: C, 57.88; H, 6.32; N, 3.91%.